|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-3-30
|
|
pubmed:abstractText |
Up-regulation of glycolysis has been demonstrated in multiple tumor types and is believed to originate as an adaptive response to the selective pressure of the tumor microenvironment. We hypothesized that ovarian cancer cells are dependent on the glycolytic pathway for adenosine triphosphate generation and that this phenotype could be exploited for therapeutic intervention.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxyglucose,
http://linkedlifedata.com/resource/pubmed/chemical/Glucose Transporter Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Intracellular Signaling Peptides...,
http://linkedlifedata.com/resource/pubmed/chemical/MTOR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-akt,
http://linkedlifedata.com/resource/pubmed/chemical/SLC2A1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1097-6868
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 Mosby, Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
202
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
371.e1-8
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:20138251-Antibiotics, Antineoplastic,
pubmed-meshheading:20138251-Antimetabolites,
pubmed-meshheading:20138251-Antineoplastic Agents,
pubmed-meshheading:20138251-Apoptosis,
pubmed-meshheading:20138251-Cell Line, Tumor,
pubmed-meshheading:20138251-Cisplatin,
pubmed-meshheading:20138251-Deoxyglucose,
pubmed-meshheading:20138251-Female,
pubmed-meshheading:20138251-Glucose Transporter Type 1,
pubmed-meshheading:20138251-Glycolysis,
pubmed-meshheading:20138251-Humans,
pubmed-meshheading:20138251-Intracellular Signaling Peptides and Proteins,
pubmed-meshheading:20138251-Ovarian Neoplasms,
pubmed-meshheading:20138251-Protein-Serine-Threonine Kinases,
pubmed-meshheading:20138251-Proto-Oncogene Proteins c-akt,
pubmed-meshheading:20138251-Sirolimus,
pubmed-meshheading:20138251-TOR Serine-Threonine Kinases
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells.
|
|
pubmed:affiliation |
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|
